Evaluation of nevirapine dosing recommendations in HIV-infected children

British Journal of Clinical Pharmacology

Volumn 76, Issue 1, 2013, Pages 137-144

  Foissac, Frantz ^a,b   Bouazza, Naïm ^a,b   Frange, Pierre ^a,c   Blanche, Stéphane ^a,c   Faye, Albert ^a,d   Lachassinne, Eric ^e   Dollfus, Catherine ^f   Hirt, Déborah ^a,b   Benaboud, Sihem ^a,b   Treluyer, Jean Marc ^a,b,g   Urien, Saïk ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HÔPITAL JEAN VERDIER   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g université Paris Cité   (France)

Author keywords

Children; Nevirapine; Population pharmacokinetics

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TRIOMUNE BABY; TRIOMUNE JUNIOR; UNCLASSIFIED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; AGE FACTORS; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; NEVIRAPINE; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 84879494792     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12069     Document Type: Article

References (34)

1. Boehringer Ingelheim Pharmaceuticals, Inc. Viramune, highlights of prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2011. Available at http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf (last accessed 10 December 2012).
2. European Medicines Agency. Viramune: EPAR product information. European Medicines Agency 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000183/WC500051481.pdf (last accessed 10 December 2012).
3. Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174: 713-721.
4. Verweel G, Sharland M, Lyall H, Novelli V, Gibb DM, Dumont G, Ball C, Wilkins E, Walters S, Tudor-Williams G. Nevirapine use in HIV-1-infected children. AIDS 2003; 17: 1639-1647.
5. Benaboud S, Ekouévi DK, Urien S, Rey E, Arrivé E, Blanche S, Gray G, Sim KL, Avit D, McIntyre J, Nerrienet E, Dabis F, Tréluyer J-M, Hirt D. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2011; 55: 331-337.
6. Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr 2003; 33: 153-156.
7. Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr 2008; 47: 334-337.
8. Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J. Acquir Immune Defic Syndr 2003; 34: 482-490.
9. Belew Y. Clinical review. Food and Drug Administration 2007. Available at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm072777.pdf (last accessed 10 December 2012).
10. European Medicines Agency. Viramune assessment report. European Medicines Agency 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000183/WC500117064.pdf (last accessed 10 December 2012).
11. De Vries-Sluijs TEMS, Dieleman JP, Arts D, Huitema ADR, Beijnen JH, Schutten M, Van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599-605.
12. la Porte CJL, Back D, Blaschke T, Boucher CAB, Fletcher CV. Updated guidelines to perform therapeutic monitoring for antiretroviral agents. Rev Antivir Ther 3: 4-12.
13. Poerksen G, Pollock L, Moons P, Chesshyre E, Burger D, Khoo S, Molyneux E. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Antivir Ther 2010; 15: 343-350.
14. Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, Fraser W, Back D, Khoo S. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother 2009; 64: 1251-1259.
15. Duong M, Buisson M, Peytavin G, Kohli E, Piroth L, Martha B, Grappin M, Chavanet P, Portier H. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 2005; 39: 603-609.
16. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: Towards Universal Access, 2010 Revision. World Health Organization, 2010; Available at http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf (last accessed 10 December 2012).
17. Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antivir Ther 2010; 15: 83-90.
18. Ellis JC, L'homme RFA, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, Van Oosterhout JJG, Chintu C, Walker AS, Gibb DM, Burger DM. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12: 253-260.
19. L'homme RFA, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, Chintu C, Burger DM, Gibb DM. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22: 557-565.
20. Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3kg to less than 6kg taking paediatric fixed dose combination tablets. AIDS 2012; 26: 1795-1800.
21. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-1038.
22. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
23. Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
24. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
25. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
26. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2010.
27. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM Jr, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med 2008; 9: 214-220.
28. Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77-82.
29. Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J 2010; 29: 940-944.
30. De Maat MMR, Huitema ADR, Mulder JW, Meenhorst PL, Van Gorp ECM, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54: 378-385.
31. Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J Antimicrob Chemother 2008; 62: 784-792.
32. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother 2012; 56: 5374-5380.
33. Recommandations du groupe d'experts. Rapport 2010 sur la prise en charge médicale des personnes infectées par le VIH sous la direction du Pr. Patrick Yéni. 2010. Available at: http://www.sante.gouv.fr/rapport-2010-sur-la-prise-en-charge-medicale-des-personnes-infectees-par-le-vih-sous-la-direction-du-pr-patrick-yeni.html (last accessed 10 December 2012).
34. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19: 1495-1499.